Three decades of heart transplantation: experience and long-term outcome

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2022-12-01 DOI:10.1080/14017431.2022.2061726

L. M. Nelson, K. Rossing, S. Boesgaard, H. Møller-Sørensen, C. Møller, F. Gustafsson, P. Olsen

{"title":"Three decades of heart transplantation: experience and long-term outcome","authors":"L. M. Nelson, K. Rossing, S. Boesgaard, H. Møller-Sørensen, C. Møller, F. Gustafsson, P. Olsen","doi":"10.1080/14017431.2022.2061726","DOIUrl":null,"url":null,"abstract":"Abstract Objectives. Heart transplantation (HTx) has become an established treatment option in patients with end-stage heart failure. The aim of this study was to report on long-term outcome over the past three decades. Design. Consecutive adult patients receiving first-time and isolated HTx from October 3, 1990, to November 2, 2020, at Rigshospitalet, Copenhagen, Denmark, were retrospectively evaluated. Data were obtained from the Scandinavian Transplant Registry and patient medical records. Recipients were grouped by time of transplantation (early era: 1990–1999; mid era: 2000–2009; recent era: 2010–2020). Results. A total of 384 recipients (77% men, median age 50 [IQR: 40–57]) were included. Median number of HTx procedures per year was 12 (10–14). Overall, 22% of patients were bridged to HTx with a mechanical circulatory support device. Median survival for the whole cohort was 13.8 years and improved numerically from the early era (12.6 years) to the mid era (14.9 years). Median survival conditional on survival to 1-year follow-up after HTx was 16.1 years. Survival probability by Kaplan–Meier method improved significantly from the mid to the recent era (log-rank p = .02). Conclusions. Heart transplantation remains an excellent treatment for selected patients with end-stage heart failure and long-term outcome has improved significantly over the past decades.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14017431.2022.2061726","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Objectives. Heart transplantation (HTx) has become an established treatment option in patients with end-stage heart failure. The aim of this study was to report on long-term outcome over the past three decades. Design. Consecutive adult patients receiving first-time and isolated HTx from October 3, 1990, to November 2, 2020, at Rigshospitalet, Copenhagen, Denmark, were retrospectively evaluated. Data were obtained from the Scandinavian Transplant Registry and patient medical records. Recipients were grouped by time of transplantation (early era: 1990–1999; mid era: 2000–2009; recent era: 2010–2020). Results. A total of 384 recipients (77% men, median age 50 [IQR: 40–57]) were included. Median number of HTx procedures per year was 12 (10–14). Overall, 22% of patients were bridged to HTx with a mechanical circulatory support device. Median survival for the whole cohort was 13.8 years and improved numerically from the early era (12.6 years) to the mid era (14.9 years). Median survival conditional on survival to 1-year follow-up after HTx was 16.1 years. Survival probability by Kaplan–Meier method improved significantly from the mid to the recent era (log-rank p = .02). Conclusions. Heart transplantation remains an excellent treatment for selected patients with end-stage heart failure and long-term outcome has improved significantly over the past decades.

查看原文本刊更多论文

三十年的心脏移植:经验和长期结果

抽象的目标。心脏移植(HTx)已成为终末期心力衰竭患者的既定治疗选择。这项研究的目的是报告过去三十年的长期结果。设计。从1990年10月3日至2020年11月2日，在丹麦哥本哈根的Rigshospitalet连续接受首次和孤立HTx的成年患者进行回顾性评估。数据来自斯堪的纳维亚移植登记处和患者医疗记录。受者按移植时间分组(早期:1990-1999;中期:2000-2009年;近期:2010-2020年)。结果。共纳入384例患者(77%为男性，中位年龄50岁[IQR: 40-57])。每年HTx手术的中位数为12例(10-14例)。总体而言，22%的患者使用机械循环支持装置桥接HTx。整个队列的中位生存期为13.8年，从早期(12.6年)到中期(14.9年)有数字上的改善。HTx术后1年随访的中位生存期为16.1年。Kaplan-Meier法的生存率从中期到近期显著提高(log-rank p = .02)。结论。在过去的几十年里，心脏移植仍然是终末期心力衰竭患者的一种很好的治疗方法，长期预后也有了显著改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.